All News

In this demanding environment, yesterday’s product launch playbook can no longer be relied upon to yield the expected patient or business outcomes, writes Boris Bogdan.

A discussion of the benefits that a cloud-based strategy has to offer.

This article is a roundtable consisting of global Medical Affairs leaders to discuss the potential of Medical Affairs as a key value driver and the role MAPS will play in bringing that potential to fruition.

Ellen Coleman outlines the highlights of a recent webinar on ensuring that patient advocacy is a key element of a market access strategy.

A variety of consultant options are available to the pharma industry; this article is a 3-step guide to selecting the right consultant.

Click the title above to open the Pharmaceutical Executive May 2018 issue in an interactive PDF format.

Insights from Partnering with IDNs: Biopharma Strategy Summit.

This article discusses the supply chain benefits of pharma companies distributing from South Florida.

This op-ed discusses the varying skills that business leaders should look at in scientists when thinking about talent for the lab and the executive suite.

Leela Barham reviews the Institute for Clinical Effectiveness Review's announced pilot program, which allow manufacturers to scrutinize executable versions of draft cost-effectiveness models.

Click the title above to open the Pharmaceutical Executive April 2018 issue in an interactive PDF format.

In terms of important clinical benefits and outcomes, modern biotech products have rarely shown the advantages of older generations of drugs, writes Bagrat Lalayan.